Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 5/20 | 0.64 |
| ▸ | MBTD1 | Q05BQ5 | 3/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.59 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | RECQL | P46063 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29956692 | 0.88 | MBTD1 (0.50) | L3MBTL3MBTD1L3MBTL1TP53BP1TSHR | |
| SCHEMBL29955283 | 0.86 | SMN1; SMN2 (0.63) | ALDH1A1SMN1; SMN2TDP1CYP2D6CYP2C9 | |
| SCHEMBL2248354 | 0.86 | SMN1; SMN2 (0.63) | ALDH1A1SMN1; SMN2TDP1CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL2279012 | 0.84 | SMN1; SMN2 (0.61) | ALDH1A1SMN1; SMN2TDP1CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL29950873 | 0.84 | SMN1; SMN2 (0.61) | ALDH1A1SMN1; SMN2TDP1CYP2D6CYP2C9 | |
| SCHEMBL1724355 | 0.84 | SMN1; SMN2 (0.60) | L3MBTL3MBTD1L3MBTL1TP53BP1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL29955383 | 0.83 | SMN1; SMN2 (0.58) | L3MBTL3MBTD1L3MBTL1TP53BP1ALDH1A1 | |
| SCHEMBL26488577 | 0.81 | ACHE (0.59) | ENPP2HRH3 | |
| SCHEMBL6212951 | 0.78 | L3MBTL3 (0.66) | L3MBTL3MBTD1L3MBTL1TP53BP1ALDH1A1 | |
| SCHEMBL23682918 | 0.78 | L3MBTL3 (1.00) | L3MBTL3MBTD1L3MBTL1TP53BP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110105346-B | Optionally substituted quinoline compounds | 卫材R&D管理有限公司 | 2023-03-10 | — | — | CN | disclosed |
| EP-3995495-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | Eisai R&D Management Co., Ltd. (JP) | 2022-05-11 | — | — | EP | disclosed |
| EP-3626717-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | Eisai R&D Management Co., Ltd. (JP) | 2020-03-25 | — | — | EP | disclosed |
| US-RE47193-E1 | Selectively substituted quinoline compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-01-08 | — | — | US | disclosed |
| US-20180354939-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-12-13 | — | — | US | disclosed |
| US-10087174-B2 | Selectively substituted quinoline compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-10-02 | — | — | US | disclosed |
| US-20180030045-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-02-01 | — | — | US | disclosed |
| US-20160326161-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-11-10 | — | — | US | disclosed |
| US-9428495-B2 | Selectively substituted quinoline compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-08-30 | — | — | US | disclosed |
| US-20150105370-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10087174-B2 | Selectively substituted quinoline compounds | SSB, TLR7, TLR8 | L3MBTL3 2773/4885MBTD1 2635/4885L3MBTL1 2863/4885 |
| US-20180030045-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | SSB, TLR7, TLR8 | L3MBTL3 2773/4885MBTD1 2635/4885L3MBTL1 2863/4885 |
| US-20180354939-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | SSB, TLR7, TLR8 | L3MBTL3 2876/4885MBTD1 2729/4885L3MBTL1 2970/4885 |
| US-20160326161-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | SSB, TLR7, TLR8 | L3MBTL3 2773/4885MBTD1 2635/4885L3MBTL1 2863/4885 |
| US-20150105370-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | SSB, TLR7, TLR8 | L3MBTL3 2773/4885MBTD1 2635/4885L3MBTL1 2863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.